← Return to Clinical trial (third line treatment) lurbinectedin and irinotecan

Discussion

Clinical trial (third line treatment) lurbinectedin and irinotecan

Pancreatic Cancer | Last Active: Jun 27, 2023 | Replies (29)
Comment receiving replies
@gamaryanne

Would you please share which gene mutation you have?
I understand from my visit last week at JH most extraordinary responders have BRCA .

Jump to this post

Replies to "Would you please share which gene mutation you have? I understand from my visit last week..."
stageivsurvivor | @stageivsurvivor | Jun 26, 2023

(g)BRCA2.

Camille Moses did not have any detectable mutations in her PDAC tumor and is an exceptional responder. She is an 11 year survivor like me. I spoke on the phone with her last Friday. Was never eligible for surgery. Has a fully functioning, intact pancreas and takes no medications.

https://seenamagowitzfoundation.org/camille-moses-pancreatic-cancer-survivor/
VIEW AND REPLY